Senior Scientific Officer

Under the leadership of Prof Chris Jones, we are seeking to appoint a Senior Scientific Officer to to carry out in vitro screening of novel transcription factor-targeting peptides in paediatric high grade glioma models.The Glioma Team at the ICR is focussed on understanding the biology of paediatric high grade glioma, such that we may improve the clinical outcome of children with these currently untreatable tumours. We have a short term position (12 months) available for an in vitro scientist to provide maternity cover for an ongoing project exploring the use of novel transcription factor-targeting peptides to disrupt tumorigenic phenotypes. We are looking for someone with experience in cancer cell culture and a range of molecular biology techniques. At a minimum you will be expected to run assays with these peptides to assess cell permeability, effects on cell viability and invasion/migration, and the impact on downstream signalling pathways. For a more experienced candidate, there are a number of other areas of work involving co-culture cell-cell interactions, epigenetic profiling, and drug screening that you could also be involved in. The role will require regular updates to be provided to our commercial partner, but also affords the opportunity to generate highly publishable data within a short time-frame. We will consider postdocs but also experienced scientists without a PhD.Key RequirementsThe successful candidate must have experience in cancer cell culture, cell viability, invasion/ migration assays and experience with in vitro experiment management and use of analytical software for drug assays. Please refer to the job description for more details of the key requirements of the role. Department/Directorate Information:The Division of Molecular Pathology is focused on understanding the molecular alterations important in the development and progression of cancer, and in determining how the disease responds to treatment. The goal is to translate advances in the molecular characterisation of tumours into approaches to successfully implement personalised cancer treatment.